Brief: Arctic Bioscience Says 12-Month Data Confirm Potential For Hro350 In Mild-To-Moderate Psoriasis
01/07/2025 16:01
July 1 (Reuters) - Arctic Bioscience AS ABSA.OL: ARCTIC BIOSCIENCE - 12-MONTH DATA CONFIRM POTENTIAL FOR HRO350 IN MILD-TO-MODERATE PSORIASIS ARCTIC BIOSCIENCE AS - HRO350 WELL TOLERATED WITH NO SAFETY CONCERNS IN STUDY ARCTIC BIOSCIENCE AS - PRIMARY ENDPOINT NOT MET DUE TO HIGH PLACEBO RESPONSE Source text: ID:nWkr5rpvl8 Further company coverage: ABSA.OL ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arctic Bioscience AS
See all newsNorway's Arctic Bioscience Q1 sales rise 78% to record on America boost
Brief: Arctic Bioscience Q1 Adjusted EBITDA NOK -6.5 Million
Norway's Arctic Bioscience 2025 revenue falls due to product recall impact
Brief: Arctic Bioscience Q3 Adjusted EBITDA NOK -7.8 Million
Brief: Arctic Bioscience H1 Adjusted EBITDA NOK -13.6 Million